Global Biomarkers Market Set To Grow To $42bn By 2022

09 August 2018
Pharma

Visiongain has launched a new pharma report Global Biomarkers Market Forecast 2017-2027: Biomarker Services, Biomarker Diagnostics, Biomarker Discovery, Genomics, Proteomics, Bioinformatics, Cancer, Cardiovascular Diseases, CNS, Autoimmune Diseases

Biomarkers can be effective in cutting the cost and time required for drug development. They can be used in drug discovery to aid the identification of drug targets in disease, as well as identifying a particular subset of a disease. Biomarkers can be used to stratify patient populations, potentially cutting the numbers of patients enrolled in trials, as well as ensuring that only those that will benefit from treatment are included. Biomarkers represent a key step towards personalised medicine, where the patient is assessed as an individual, rather than by their disease.

Nasreen Uddin, a pharmaceutical industry analyst for visiongain, said “The Biomarkers Market has seen strong growth over the recent years, driven by high demand for diagnostics detecting genomic and proteomic markers as companion diagnostics for novel therapies, increased R&D funding and the rising prevalence of oncology and cardiovascular-based disease. In addition, the shift from monoplex to multiplex biomarker testing to tackle complex diseases will continue to accentuate the growth in the market.

Regulatory bodies have continued their commitment to personalised medicine with the release of draft guidance’s for genomic biomarkers and the development of companion diagnostics. Government initiatives and public and private partnerships will create significant opportunities in the biomarker market during the forecast period.”

Leading companies featured in the report include Quintiles IMS Holdings Inc, Laboratory Corporation of America Holdings, Parexel, Charles River Laboratories, ICON plc, WuXi PharmaTec, Caprion Proteomics, Proteome Sciences, Pacific Biomarkers, Oxford Gene Technology (OGT), Worldwide Clinical Trials (WWC), Agilent, AB SCIEX, QIAGEN, Axela Inc
Thermo Fisher Scientific, Quest Diagnostics, Myriad Genetics, Genomic Health, Critical Diagnostics, Epigenomics, MDxHealth (formerly OncoMethylome)

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Generic Drugs market set to grow to $424bn by 2024” says new Visiongain report

Visiongain believes the market will see more traditional pharma companies beginning to embrace the generic business in order to take advantage of higher growth rates in this area.

14 June 2019

Read

“Global Precision Cancer Diagnostic Tests market set to grow to $21.3bn by 2024” says new Visiongain report

The market players are increasingly focusing on precision therapies where drug and precision tests are developed simultaneously.

06 June 2019

Read

“Global Antifungal Drugs market set to grow to $17bn by 2024” says new Visiongain report

Market penetration and adoption of new technologies entering the market for antifungal drugs will be crucial for market growth.

04 June 2019

Read

“Global Ophthalmic Equipment market set to grow to $75bn by 2024” says new Visiongain report

here is a growing demand for ophthalmic equipment such as vision care products and ophthalmology surgical devices, mainly due to the increasing incidence of myopia across the world.

03 June 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever